ReviewClinical kidney journal2026
Preserving residual kidney function in peritoneal dialysis: from conventional approaches to contemporary practice.
Review in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Residual kidney function (RKF) is a key determinant of outcomes in patients undergoing peritoneal dialysis (PD), contributing to solute clearance, volume regulation, reduced inflammation, and improved survival. Nevertheless, RKF commonly declines after PD initiation, often due to potentially modifiable clinical and treatment-related factors. This narrative review summarizes current evidence on the mechanisms underlying RKF loss in PD and evaluates established and emerging strategies to preserve RKF in contemporary practice. Major contributors to RKF decline include hemodynamic instability, cumulative glucose exposure, inflammation and peritonitis, nephrotoxic medications, dialysis-related volume shifts, and kidney disease-specific conditions. Conventional strategies such as incremental and individualized PD prescriptions, use of biocompatible and glucose-sparing solutions, careful volume and blood pressure management, renin-angiotensin-aldosterone system blockade, infection prevention, and tailored management after kidney allograft failure are reviewed. Importantly, current guideline-based strategies largely address these factors in isolation. We propose that RKF preservation should be approached through an integrated, mechanism-based framework, in which cumulative glucose exposure represents a central modifiable mediator linking multiple pathways of kidney injury. In this context, remote monitoring and artificial intelligence-based tools may serve as enabling platforms that integrate longitudinal clinical and treatment data, supporting individualized and proactive care. Preserving RKF should remain a central therapeutic goal in PD, and combining established physiological principles with modern digital technologies may provide a more effective framework for improving long-term patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.